Epilepsy: A Comprehensive Disease Characterization

Autonomous discovery report — 15 confirmed findings, 62 papers reviewed across 5 iterations

Disease: Epilepsy | Category: Complex (multifactorial, genetically heterogeneous) | Suggested MONDO: MONDO:0005027

Summary

Epilepsy is a common, chronic, and etiologically heterogeneous brain disorder affecting roughly 50–70 million people worldwide, defined by an enduring predisposition to recurrent unprovoked seizures arising from abnormal, hypersynchronous neuronal discharge (PMID: 41306289). Despite dozens of distinct etiologies—monogenic channelopathies, polygenic susceptibility, structural brain lesions, perinatal injury, stroke, traumatic brain injury (TBI), CNS infection, autoimmune processes, and metabolic disease—the disorder converges mechanistically on a single core theme: a shift in the excitation/inhibition (E/I) balance toward excitation. This shift is driven by ion-channel and neurotransmitter-receptor dysfunction, loss or silencing of GABAergic inhibitory interneurons, microglial pruning of inhibitory synapses, neuroinflammation, blood–brain-barrier (BBB) disruption, and maladaptive epigenetic and circuit reorganization.

Epilepsy's genetic architecture is predominantly polygenic (overall heritability ≈ 32%; 26 genome-wide-significant loci converging on synaptic genes in excitatory and inhibitory neurons), with important monogenic subsets—most notably SCN1A loss-of-function variants that cause > 95% of Dravet syndrome and span a phenotypic continuum from mild febrile seizures (GEFS+) to severe developmental and epileptic encephalopathy. Clinically, antiseizure medications (ASMs) control seizures in ~70–80% of patients, while ~30% have drug-resistant epilepsy requiring surgery, neuromodulation, dietary therapy, or emerging precision/gene therapies. Sudden unexpected death in epilepsy (SUDEP) is the leading cause of premature mortality in refractory disease (8–17% of epilepsy-related deaths).

A crucial public-health message emerges from this work: a large fraction of the global epilepsy burden is preventable. The four leading modifiable etiologic categories—perinatal insults, TBI, CNS infection (notably neurocysticercosis), and stroke—are addressable through obstetric care, injury prevention, sanitation/vaccination, and vascular risk control. Global incidence and prevalence are rising (driven disproportionately by acquired/secondary epilepsy), even as age-standardized DALYs and mortality decline—an epidemiologic transition with major implications for low- and middle-income countries (LMICs). Cutting-edge epigenetic, single-cell, and spatial-transcriptomic studies are now resolving epileptogenesis at cellular and molecular resolution, identifying "epilepsy-associated microglia," complement activation, and an epigenetic "cellular memory" that together offer new biomarkers and therapeutic targets.

Disease Information (Section 1)

Epilepsy is a chronic neurological disorder characterized by an enduring predisposition to recurrent, unprovoked seizures resulting from abnormal, excessive, and hypersynchronous neuronal discharges. It is not a single disease but a family of syndromes classified by seizure type (focal, generalized, combined, unknown) and etiology (genetic, structural, metabolic, immune, infectious, unknown), per the International League Against Epilepsy (ILAE) framework.

Key identifiers (aggregated disease-level resources):

Synonyms / alternative names: seizure disorder; "the epilepsies"; historically "falling sickness." Subtype names include genetic generalized epilepsy (GGE), temporal lobe epilepsy (TLE), developmental and epileptic encephalopathy (DEE), Dravet syndrome, Lennox–Gastaut syndrome (LGS), and genetic epilepsy with febrile seizures plus (GEFS+).

Data source note: This report is derived primarily from aggregated, disease-level resources (GWAS meta-analyses, GBD modeling, ILAE task-force reports, systematic reviews, model-organism studies) rather than individual patient EHR records, though several cited studies are single-center clinical cohorts.

Key Findings

F001 — Epilepsy is a common chronic brain disorder with rising global burden

Epilepsy affects approximately 70 million individuals globally, with pathogenesis primarily attributed to recurrent seizures caused by abnormal neuronal discharges (PMID: 41306289). GBD 2023–based deep-learning modeling projects that the age-standardized prevalence rate in LMICs will reach 907.22 per 100,000 by 2050 (95% UI 731.01–1083.56), a 33.32% increase from 2023 (PMID: 42541262). Critically, the increase in secondary (acquired) epilepsy is more than 7-fold that of idiopathic epilepsy since 2023, signaling a shift in the etiologic composition of the global burden toward preventable, acquired causes.

"Epilepsy is a prevalent chronic neurological disorder, affecting approximately 70 million individuals globally, with its pathogenesis primarily attributed to recurrent seizures caused by abnormal neuronal discharges in the brain." — PMID: 41306289

F002 — SCN1A loss-of-function causes >95% of Dravet syndrome

Dravet syndrome (DS), the prototypical genetic epileptic encephalopathy, is caused by heterozygous loss-of-function variants in SCN1A, encoding the voltage-gated sodium channel α-1 subunit (Naᵥ1.1); over 95% of cases carry such variants (PMID: 41712149, PMID: 40836583). Naᵥ1.1 is preferentially expressed in GABAergic interneurons, so its loss selectively impairs inhibition—a molecular explanation for the E/I imbalance. Computational stability analysis found pathogenic missense variants significantly more destabilizing than benign variants (FoldX ΔΔG 2.61 vs 0.31 kcal/mol) (PMID: 42490276), yet variants at the same codon can produce divergent gain- vs complete loss-of-function effects (e.g., I1347T/V/F mixed function vs I1347N complete LoF), cautioning against position-based effect prediction (PMID: 41718449).

"Over 95% of cases are caused by loss-of-function pathogenic variants in SCN1A, the gene encoding the voltage-gated sodium channel alpha-1 subunit." — PMID: 41712149

HGNC/gene annotation: SCN1A (HGNC:10585), SCN1B (HGNC:10586), SCN2A, GABRB3, GABRA1, GRIN1, GRIN2B, CACNA1A, CHD2, MTOR, ALG13, DEPDC5.

F003 — Epileptogenesis involves E/I imbalance, microglial pruning of inhibitory synapses, and neuroinflammation

In epileptic mice, hyperactive inhibitory neurons activate microglia via GABAergic signaling, and these activated microglia preferentially phagocytose inhibitory synapses, disrupting E/I balance and amplifying network excitability (PMID: 40425792). Pro-inflammatory cytokines reinforce this: IL-1β promotes neuronal hyperexcitability, IL-6 mediates neuroinflammation, and TNF-α disrupts the E/I balance (PMID: 41306289). In focal cortical dysplasia (FCD) models, the balance of inhibitory/excitatory synaptic currents shifts toward excitation in perilesional cortex, rendering it seizure-prone (PMID: 40003890).

"these activated microglia preferentially phagocytose inhibitory synapses, disrupting the balance between excitatory and inhibitory synaptic transmission and amplifying network excitability." — PMID: 40425792

GO terms: GABAergic synaptic transmission (GO:0051932), synapse pruning (GO:0098883), microglial cell activation (GO:0001774), inflammatory response (GO:0006954). CL terms: GABAergic interneuron (CL:0000617), microglial cell (CL:0000129), glutamatergic neuron (CL:0000679), astrocyte (CL:0000127).

F004 — SUDEP is the leading cause of epilepsy-related premature mortality

SUDEP accounts for 8–17% of epilepsy-related deaths (PMID: 42617006). Risk is elevated by refractory epilepsy, poor seizure control (frequent generalized tonic-clonic seizures), polytherapy, nocturnal/sleep-related seizures, and genetic predisposition. Mechanisms center on neuro-cardio-respiratory dysfunction: autonomic dysfunction, impaired heart-rate variability, seizure-related tachy-/bradyarrhythmias, and altered QT dynamics. Molecular autopsy implicates channelopathy genes DEPDC5, SCN1A, and cardiac ion-channel genes. Stress and HPA-axis dysfunction further contribute to SUDEP risk (PMID: 42556144).

"Sudden unexpected death in epilepsy (SUDEP) represents a major cause of mortality in individuals with epilepsy, accounting for 8-17% of epilepsy-related deaths." — PMID: 42617006

F005 — Acquired epilepsies follow brain insults via inflammation, neuron loss, and circuit reorganization

The most common acquired epilepsies arise after acute brain insults—TBI, stroke, or CNS infections (PMID: 29247482). Shared cross-etiology risk factors include intracranial bleeding, blood–brain-barrier disruption, more severe injury, and early seizures within 1 week of injury; common histopathology includes microglial activation, astrogliosis, heterotopic white-matter neurons, neuron loss, and inflammatory infiltrates. Temporally, most seizure recurrences occur within 1–2 years of the insult, with risk declining sharply thereafter—defining a critical window for anti-epileptogenic intervention (PMID: 40824375).

"Risk factors for developing epilepsy that appear common to multiple acute injury etiologies include intracranial bleeding, disruption of the blood-brain barrier, more severe injury, and early seizures within 1 week of injury." — PMID: 29247482

F006 — High burden of bidirectional psychiatric, cognitive, and neurodevelopmental comorbidities

People with epilepsy (PWE) have disproportionately high rates of depression, anxiety, ADHD, autism spectrum disorder, functional/dissociative seizures, and cognitive impairment, many with bidirectional relationships with epilepsy (PMID: 41868310). In structured inpatient screening, ~1 in 5 patients received a psychiatric diagnosis, and 37% of those had not been previously diagnosed (PMID: 41235437). Pediatric epilepsy is commonly accompanied by anxiety, depression, attention difficulties, and executive dysfunction (PMID: 40612818). Post-surgical memory decline affects 40–60% of patients (PMID: 41427594).

"Many of these disorders have bidirectional relationships with epilepsy, reflecting overlapping biological, psychological, and social mechanisms." — PMID: 41868310

F007 — Genetic mouse models recapitulate Dravet syndrome and enable precision therapy

Scn1a⁺/⁻ (haploinsufficient) mice model SCN1A-derived epilepsy with spontaneous seizures and susceptibility to hyperthermia-, 6 Hz-, and PTZ-induced seizures, and are used to test intranasal nanoparticle-encapsulated neuropeptide Y (NP-NPY) and interneuron-targeted AAV gene therapy (PMID: 41074603, PMID: 40106582). Scn1b-null mice model DS with spontaneous generalized seizures beginning in the second week of life plus ataxia from cerebellar Purkinje-cell hypoexcitability (PMID: 40923316). DS carries a 10–20% rate of premature death, recapitulated in models (PMID: 40106582).

"Scn1b null mice model DS, with spontaneous generalized seizures that start in the second week of life." — PMID: 40923316

F008 — Complex polygenic architecture with monogenic subsets converging on synaptic/ion-channel genes

A multi-ancestry GWAS meta-analysis of 29,944 cases and 52,538 controls identified 26 genome-wide-significant loci (19 specific to genetic generalized epilepsy, GGE) and 29 likely causal genes; common variants explain 39.6–90% of genetic risk for GGE, with gene-set analyses implicating synaptic processes in both excitatory and inhibitory neurons (PMID: 37653029). Overall epilepsy heritability is ~32% (PMID: 39904507), with ≥ 400 estimated common causal variants (PMID: 25063994). Exome sequencing of epileptic encephalopathies found excess de novo mutations in intolerant genes including GABRB3, ALG13, CACNA1A, CHD2, GABRA1, GRIN1, GRIN2B, MTOR, SCN2A (PMID: 41726570).

"We identify 26 genome-wide significant loci, 19 of which are specific to genetic generalized epilepsy (GGE). We implicate 29 likely causal genes underlying these 26 loci." — PMID: 37653029

F009 — ASMs control ~70–80% of patients; ~30% are drug-resistant

Conventional ASMs (phenytoin, valproate, levetiracetam, lamotrigine, carbamazepine) control seizures in 70–80% of patients, while ~30% experience drug resistance or intolerable side effects (PMID: 41496926). For drug-resistant epilepsy (DRE): resective surgery, ketogenic diet, vagus nerve stimulation (VNS), responsive neurostimulation (RNS, 50–70% efficacy), deep brain stimulation (DBS), and cannabidiol (~30–50% seizure reduction). Everolimus (mTOR inhibitor) is the only precision therapy with class I evidence for seizures (in tuberous sclerosis complex, TSC) (PMID: 40411479). A ~75% treatment gap persists in low-income countries (PMID: 41496926).

"Cannabidiol (CBD) demonstrates a 30-50% seizure reduction, while responsive neurostimulation (RNS) achieves 50-70% efficacy, especially in drug-resistant epilepsy." — PMID: 41496926

F010 — Canine idiopathic epilepsy is a naturally occurring cross-species model

Idiopathic epilepsy (IE) is the most common chronic neurological disease in dogs and an established natural model for human epilepsy of genetic/unknown etiology (PMID: 40707505, PMID: 39804158). Dogs resemble humans in etiology and disease course; BBB dysfunction was detected by DCE-MRI in 37% of seizing dogs, with TGF-β pathway activation in piriform cortex (PMID: 31032909). Canine IE plasma/fecal metabolomes show altered oxidative stress, inflammation, amino-acid metabolism (lower vitamin B6), and gut-microbiome shifts paralleling human findings.

"Idiopathic epilepsy (IE) is the most common chronic neurological disease in dogs, and a natural animal model for human epilepsy types with genetic and unknown etiology." — PMID: 40707505

F011 — A substantial fraction of epilepsy is preventable

The ILAE Prevention Task Force identifies four preventable etiologic categories: perinatal insults, TBI, CNS infection, and stroke (PMID: 29637551). Perinatal brain insults are the largest attributable fraction in children (~15% HIC, 17% LMIC); stroke accounts for ≥50% of new-onset cases in older adults; TBI ~5%; CNS infections ~5% in LMIC. Median active-epilepsy prevalence is 7.0/1000 in high-income and 11.1/1000 in low/middle-income countries. Neurocysticercosis is a leading preventable cause in endemic regions, addressable via sanitation and clean water (PMID: 40347840).

"Perinatal brain insults were the largest attributable fraction of preventable etiologies in children, with median estimated fractions of 17% in LMIC and 15% in HIC. Stroke was the most common preventable etiology among older adults." — PMID: 29637551

F012 — SCN1A variants span a phenotypic continuum (GEFS+ → Dravet)

Genetic epilepsy with febrile seizures plus (GEFS+) is an autosomal dominant disorder with febrile or afebrile seizures exhibiting marked phenotypic variability, forming part of the SCN1A spectrum (PMID: 35627139). The same gene thus produces a severity continuum from mild febrile seizures (GEFS+) to severe DEE (Dravet), with incomplete penetrance and highly variable expressivity, and same-codon variants yielding divergent functional effects (PMID: 41718449).

F013 — Rising incidence/prevalence but falling age-standardized DALYs and mortality; secondary epilepsy grows fastest

From 1990–2021, both China and the world showed increasing incidence and prevalence, while DALYs and mortality decreased significantly (global AAPC −0.525% DALYs, −0.535% mortality), with projected continued increases in incidence/prevalence but ongoing DALY/mortality declines to 2045 (PMID: 42404107). GBD 2023 modeling projects LMIC age-standardized prevalence of 907/100,000 by 2050, with idiopathic and secondary epilepsy ASPRs of 323 and 584 per 100,000 respectively (PMID: 42541262).

"From 1990 to 2021, both China and the world showed increasing trends in incidence and prevalence. In contrast, DALYs and mortality decreased significantly." — PMID: 42404107

F014 — Epigenetic reprogramming forms a "cellular memory" of epileptogenesis

The ILAE Genetics/Epigenetics Task Force established epigenetics—DNA methylation, histone post-translational modification, and noncoding RNAs—as important mechanisms controlling gene activity in epilepsy, with potential as biomarkers and novel therapies (PMID: 32301721). Experimental status epilepticus triggers spatiotemporal hypo- and hypermethylation genome-wide, and manipulations that alter DNA methylation ameliorate cognitive and hyperexcitability phenotypes (PMID: 30159897). In a hippocampal neuron model, glutamate-driven excitation produced lasting histone modifications and promoter hypermethylation repressing glutamate-receptor genes Gria2 and Grin2a, forming a "cellular memory of epileptogenesis" (PMID: 29089052). MicroRNAs (e.g., miR-134) are candidate biomarkers and antiseizure targets.

"we hypothesized that epigenetic modifications may form the basis for a cellular memory of epileptogenesis." — PMID: 29089052

F015 — Single-cell/spatial transcriptomics reveals cell-type-specific hippocampal remodeling in TLE

Single-nucleus RNA-seq of hippocampus after pilocarpine status epilepticus showed reductions in specific Cck and Lamp5-Lhx6 GABAergic interneuron subclusters, increases in Cajal–Retzius cells and dentate granule-cell precursors, and a markedly expanded microglial subcluster termed "epilepsy-associated microglia" (EAM) whose profile overlaps microglia in Alzheimer's disease and TBI models (PMID: 41867871). Integrative single-cell + spatial transcriptomics in TLE with hippocampal sclerosis (TLE-HS) found complement activity elevated and higher in sclerotic than normal hippocampus (PMID: 42458112). Bulk + snRNA-seq implicate myeloid/microglial immune infiltration and hub genes (PSD4, P2RY13) in hippocampal sclerosis (PMID: 41456035).

"Complement activity was elevated in epilepsy. The levels were higher in hippocampal sclerosis (HS) tissue than in normal hippocampus." — PMID: 42458112

Detailed Section-by-Section Characterization

Section 2 — Etiology, Risk & Protective Factors

Causal factors span genetic (channelopathies, synaptopathies, polygenic risk), structural (FCD, hippocampal sclerosis, tumors, malformations), infectious (neurocysticercosis, meningitis/encephalitis), metabolic, immune (autoimmune encephalitis), and unknown categories.

• Genetic risk factors: Monogenic causal variants (SCN1A, SCN2A, KCNQ2, GABRB3, DEPDC5, MTOR, GRIN2B), 26 GGE susceptibility loci, and polygenic risk scores (≥400 common causal variants; heritability ~32%) (F008; PMID: 37653029, PMID: 25063994).
• Environmental/acquired risk factors: TBI, stroke, CNS infection, perinatal insults, early-life seizures, intracranial bleeding, BBB disruption, febrile seizures (F005, F011). Age (bimodal: young children and elderly), family history, and stress/HPA-axis dysfunction (PMID: 42556144).
• Protective/modifiable factors: Vaccination and sanitation (against neurocysticercosis/CNS infection), obstetric care, injury prevention, vascular risk-factor control, and seizure-control measures reducing SUDEP risk (F011).
• Gene–environment interactions: Genetic susceptibility (e.g., low seizure threshold) interacts with environmental triggers (fever in Dravet/GEFS+; stress; sleep deprivation). Gut-microbiota–host epigenetic interactions may modulate treatment response (PMID: 42236101).

Section 3 — Phenotypes (with HPO terms)

Characteristics: Onset ranges from neonatal to geriatric; severity from mild (self-limited GEFS+) to severe (DEE with premature death). Course is typically episodic/fluctuating (seizures) superimposed on a chronic disorder; some DEEs are progressive. Quality-of-life impact is substantial—driving restrictions, employment barriers, stigma, psychiatric comorbidity, and cognitive decline (F006).

Section 4 — Genetic / Molecular Information

Causal genes (F002, F008): SCN1A (Naᵥ1.1, Dravet/GEFS+), SCN1B, SCN2A, KCNQ2, GABRB3, GABRA1, GRIN1, GRIN2B, CACNA1A, CHD2, MTOR (mTORopathies/FCD), DEPDC5, ALG13, TSC1/TSC2 (TSC). Variant types: missense (often destabilizing), frameshift, nonsense, splice-site, and structural. Functional consequences: predominantly loss-of-function in Dravet (Naᵥ1.1 in interneurons → disinhibition), but gain-of-function in some SCN2A/SCN8A and GRIN variants. Same-codon divergence complicates ACMG/AMP classification (PMID: 41718449). Somatic mosaicism in MTOR drives FCD (non-cell-autonomous epileptogenesis; PMID: 34180075). Epigenetic: DNA methylation, histone modification, ncRNA dysregulation (F014). Chromosomal: microdeletions/duplications (e.g., 15q13.3) detectable by CMA; pathogenic CNVs found in 52% of an ASD-epilepsy overlap cohort by microarray (PMID: 42207445).

Section 5 — Environmental Information

Toxins/withdrawal (alcohol), perinatal hypoxia-ischemia, TBI, radiation, and pollution contribute. Lifestyle factors: sleep deprivation, alcohol, and stress are seizure triggers; the gut–brain axis and diet modulate seizure susceptibility (PMID: 42236101). Climate change is an emerging environmental influence on neurological burden (PMID: 42626786). Infectious agents: Taenia solium (neurocysticercosis; leading preventable cause in endemic regions), bacterial/viral meningoencephalitis (F011; PMID: 40347840).

Section 6 — Mechanism / Pathophysiology

The unifying mechanism is excitation/inhibition imbalance (see Mechanistic Model). Molecular pathways: GABAergic/glutamatergic signaling, mTOR pathway (TSC/FCD mTORopathies; PMID: 34298906, PMID: 34180075), TGF-β/BBB signaling, complement cascade, and cytokine (IL-1β/IL-6/TNF-α) signaling. Cellular processes: microglial synapse pruning, astrogliosis, neuroinflammation, neuronal loss, aberrant neurogenesis, synaptic reorganization (mossy-fiber sprouting). Protein dysfunction: Naᵥ1.1 loss-of-function/misfolding (F002). Metabolic changes: oxidative stress, altered amino-acid metabolism, vitamin B6 depletion (canine parallel; F010). Immune involvement: autoimmune epilepsy responsive to immunotherapy (PMID: 40249641); NORSE responsive to IL-6 blockade (tocilizumab; PMID: 40100558); Mendelian randomization links polymyositis to epilepsy via T-cell/microglial neuroinflammation (PMID: 41466027). Molecular profiling: single-cell/spatial transcriptomics reveal EAM and complement activation (F015).

Ontology annotation: GO:0006954 (inflammatory response), GO:0098883 (synapse pruning), GO:0051932 (GABAergic transmission), GO:0032526 (response to fever), CL:0000617 (GABAergic interneuron), CL:0000129 (microglia), UBERON:0001954 (Ammon's horn/hippocampus). CHEBI: GABA (CHEBI:16865), glutamate (CHEBI:14321), cannabidiol (CHEBI:69478).

Section 7 — Anatomical Structures Affected

• Organ: brain (UBERON:0000955); body system: nervous system (UBERON:0001016). Secondary: cardiovascular (SUDEP arrhythmias), respiratory (peri-ictal apnea), endocrine (HPA axis).
• Tissue/cell: nervous tissue; GABAergic interneurons (CL:0000617), glutamatergic pyramidal neurons (CL:0000679), microglia (CL:0000129), astrocytes (CL:0000127), cerebellar Purkinje cells (CL:0000121, Dravet ataxia).
• Subcellular: ion channels at the plasma membrane/axon initial segment (GO:0043194); nucleus (epigenetic/DNA methylation); mitochondria (metabolic/oxidative stress).
• Localization: commonly hippocampus (UBERON:0001954), temporal lobe (UBERON:0001871), neocortex; often unilateral in mesial TLE-HS, bilateral/generalized in GGE. FCD is focal.

Section 8 — Temporal Development

Onset: bimodal—early childhood (genetic/DEE, perinatal) and older adults (stroke-related). Onset pattern: may be acute (post-insult) or insidious (genetic). Progression: most epilepsies are chronic/lifelong with an episodic seizure course; DEEs may be progressive with developmental plateau/regression; adult Dravet shows accelerated-aging neuropathology (PMID: 40956029). Critical periods: acquired-epilepsy recurrence risk peaks within 1–2 years of insult (F005), defining an anti-epileptogenic intervention window. Remission: ~65–70% achieve treatment-induced remission; some childhood syndromes remit spontaneously.

Section 9 — Inheritance and Population

• Epidemiology: ~50–70 million affected worldwide; active-epilepsy prevalence 7.0/1000 (HIC) and 11.1/1000 (LMIC) (F001, F011). Rising incidence/prevalence, falling age-standardized DALYs/mortality (F013).
• Inheritance: predominantly multifactorial/polygenic; monogenic subsets are autosomal dominant (GEFS+, most Dravet as de novo), with incomplete, age-dependent penetrance and highly variable expressivity (F012). Some AR and mitochondrial forms exist. De novo mutations are common in DEEs (F008).
• Demographics: slight variation by sex/geography; LMICs bear disproportionate acquired burden; neurocysticercosis endemic in Latin America, sub-Saharan Africa, and parts of Asia (PMID: 8490989).

Section 10 — Diagnostics

• Electrophysiology: EEG is the cornerstone; abnormal EEG is the strongest independent predictor of epilepsy (OR 48.96 in an ASD cohort; PMID: 42207445); intracranial EEG for surgical planning.
• Imaging: MRI (FCD, hippocampal sclerosis, lesions), PET, DCE-MRI for BBB (translational; PMID: 31032909).
• Genetic testing: gene panels, WES, WGS, CMA/karyotype; high yield in DEE and early-onset epilepsy (GTR/ClinVar/GeneReviews). Molecular autopsy for SUDEP.
• Labs/biomarkers: autoantibody panels (autoimmune epilepsy), metabolic workup; emerging miRNA (miR-134) and complement biomarkers (F014, F015).
• Clinical criteria: ILAE operational definition and classification; differential diagnosis includes syncope, functional/dissociative seizures (PMID: 39510015), migraine, and movement disorders.

Section 11 — Outcome / Prognosis

~70–80% achieve seizure control; ~30% remain drug-resistant (F009). SUDEP is the leading cause of premature death (8–17% of epilepsy deaths; F004). DS carries 10–20% premature mortality (F007). Morbidity is driven by injury, psychiatric/cognitive comorbidity (F006), and reduced QoL. Prognostic factors: etiology, seizure frequency/type (GTCS), drug response, EEG/imaging findings, and genetic diagnosis. Post-surgical memory decline affects 40–60% (PMID: 41427594).

Section 12 — Treatment (with NCIT suggestions)

Treatment strategy: mechanism/syndrome-guided (e.g., avoid sodium-channel blockers in Dravet); seizure-type-specific in LGS (PMID: 40409093, PMID: 41391422); precision therapy by genotype (PMID: 40411479).

Section 13 — Prevention

Primary: obstetric/perinatal care, TBI prevention, stroke risk-factor control, vaccination and sanitation against CNS infection/neurocysticercosis (F011; PMID: 29637551, PMID: 40347840). Secondary: early seizure detection, EEG screening in high-risk groups (e.g., ASD; PMID: 42207445). Tertiary: SUDEP risk communication and safety counseling (PMID: 42208388, PMID: 42435512), medication adherence, comorbidity management, and genetic counseling for heritable subtypes.

Section 14 — Other Species / Natural Disease

Dogs (Canis lupus familiaris, NCBI:txid9615) develop naturally occurring idiopathic epilepsy—the most common canine chronic neurological disease—recapitulating human etiology, disease course, BBB dysfunction, and metabolomic shifts (F010; PMID: 40707505, PMID: 31032909, PMID: 42280378). This provides strong evolutionary conservation of epileptogenic mechanisms and translational value. Orthologous SCN1A exists across mammals. Epilepsy itself is non-transmissible; its infectious cause neurocysticercosis is transmitted via the T. solium lifecycle involving pigs.

Section 15 — Model Organisms

• Mouse (Mus musculus, NCBI:txid10090): Scn1a⁺/⁻ and Scn1b-null Dravet models (F007); pilocarpine/kainate chemoconvulsant TLE models; freeze-lesion FCD models; MTOR-mosaic FCD models (PMID: 34180075). Genetic tools: knockout, conditional, humanized. Resources: MGI, IMPC.
• Rat: freeze-induced neocortical malformation, pilocarpine status epilepticus (PMID: 40003890, PMID: 29089052); RGD.
• In vitro/cellular: cultured hippocampal neurons (epigenetic memory; PMID: 29089052), iPSC-derived neurons, organoids.
• Phenotype recapitulation: models reproduce spontaneous seizures, interneuron dysfunction, premature death (Dravet), and BBB/inflammation; limitations include incomplete replication of the human cognitive/behavioral comorbidity spectrum and genetic-background effects.

Mechanistic Model / Interpretation

The findings cohere into a convergent E/I-imbalance model in which diverse etiologies funnel into a common final pathway of hyperexcitable, hypersynchronous networks:

   ETIOLOGIC TRIGGERS (upstream, heterogeneous)
   ┌───────────────────────────────────────────────────────────┐
   │ Genetic          Acquired insults        Structural/Immune  │
   │ • SCN1A LoF       • TBI                   • FCD (MTOR mosaic)│
   │ • GABRB3, GRIN…   • Stroke                • Hippocampal scler│
   │ • Polygenic (26   • CNS infection         • Autoimmune (Ab)  │
   │   GWAS loci)      • Perinatal insult      • NORSE (IL-6)     │
   └───────────────┬───────────────────┬───────────────────────┘
                   │                   │
      Loss of interneuron       BBB disruption + TGF-β
      inhibition (Nav1.1↓)      + cytokines (IL-1β,IL-6,TNF-α)
                   │                   │
                   ▼                   ▼
        ┌─────────────────────────────────────────┐
        │   NEUROINFLAMMATION & GLIAL REMODELING   │
        │  • Microglial pruning of INHIB. synapses │
        │  • "Epilepsy-associated microglia" (EAM) │
        │  • Astrogliosis, complement activation   │
        └───────────────────┬─────────────────────┘
                            ▼
        ┌─────────────────────────────────────────┐
        │   E / I  IMBALANCE  → NET EXCITATION      │  ← core convergent node
        └───────────────────┬─────────────────────┘
                            ▼
        ┌─────────────────────────────────────────┐
        │  EPIGENETIC "CELLULAR MEMORY"            │  (feed-forward, self-reinforcing)
        │  • DNA methylation of Gria2/Grin2a       │
        │  • Histone modifications, miR-134        │
        │  • Circuit reorganization (sprouting)    │
        └───────────────────┬─────────────────────┘
                            ▼
   HYPERSYNCHRONOUS DISCHARGE → RECURRENT SEIZURES (clinical epilepsy)
                            │
          ┌─────────────────┼──────────────────────┐
          ▼                 ▼                      ▼
   Psychiatric/cognitive  Drug resistance     SUDEP (neuro-cardio-
   comorbidity (bidir.)   (~30%)              respiratory failure)

Upstream vs downstream: Etiologic triggers and interneuron/inhibition loss are upstream; neuroinflammation and glial synapse-pruning are intermediate amplifiers; the epigenetic "cellular memory" and circuit reorganization are feed-forward mechanisms that render epilepsy self-sustaining and chronic; seizures, comorbidity, drug resistance, and SUDEP are downstream clinical manifestations. This model explains why a single mechanism (disinhibition) can arise from a sodium-channel mutation, a somatic mTOR mutation, a stroke, or an autoimmune attack—and why immunomodulation, neuromodulation, dietary, and precision-genetic approaches can each intercept the pathway at different nodes.

Evidence Base

Supporting/converging evidence: Autoimmune epilepsy responsive to immunotherapy (PMID: 40249641), NORSE responsive to tocilizumab (PMID: 40100558), and Mendelian-randomization linking polymyositis to epilepsy via neuroinflammation (PMID: 41466027) all reinforce the inflammatory arm of the model. Non-cell-autonomous FCD epileptogenesis (PMID: 34180075) illustrates how few mutant neurons induce network-level hyperexcitability.

Limitations and Knowledge Gaps

1. Mechanism causality vs correlation: Much single-cell/epigenetic data (F014, F015) is associative or from rodent status-epilepticus models; whether EAM and complement activation are drivers or consequences of seizures requires causal perturbation in humans.
2. Genetic architecture incompleteness: Despite 26 GWAS loci and heritability of 32%, substantial "missing heritability" remains; ≥400 causal variants are estimated but most are unidentified (F008).
3. Variant interpretation: Same-codon functional divergence (F002/F012) undermines position-based prediction, leaving many SCN1A variants as VUS and complicating precision therapy.
4. Model-organism translation: Mouse Dravet models recapitulate seizures and premature death but incompletely model human cognitive/behavioral comorbidities and genetic-background modifiers (F007).
5. Comorbidity underdiagnosis: 37% of psychiatric comorbidity is undetected in routine care (F006), and QoL data are heterogeneous and often not phenotype-specific.
6. LMIC data gaps: GBD projections rely on modeling with wide uncertainty intervals (F001, F013); primary epidemiologic data from LMICs remain sparse.
7. Precision therapy scarcity: Only everolimus has class I precision evidence (F009); gene/RNA therapies remain largely preclinical.
8. Report scope: This is a literature-synthesis report (no primary dataset analyzed); citation snippets were validated against abstracts, but some claims rest on single studies.

Proposed Follow-up Experiments / Actions

1. Causal test of microglial pruning: Conditional depletion or complement (C1q/C3) blockade in Dravet and post-TBI models to determine whether preventing inhibitory-synapse phagocytosis is anti-epileptogenic (extends F003, F015).
2. Epigenetic therapy trials: Test DNA-methylation modulators and antimiR-134 in the 1–2-year post-insult critical window (F005, F014) as anti-epileptogenic interventions after TBI/stroke.
3. Functional variant screening: High-throughput deep mutational scanning of SCN1A to resolve VUS and enable genotype-matched precision therapy, addressing same-codon divergence (F002, F012).
4. Biomarker validation: Prospectively validate circulating miR-134, complement components, and BBB permeability (DCE-MRI) as predictive biomarkers of epileptogenesis and drug resistance across species (F010, F014, F015).
5. Preventive public-health modeling: Quantify epilepsy cases avertable by scaling perinatal care, TBI prevention, stroke control, and neurocysticercosis elimination in LMICs to guide investment (F011, F013).
6. SUDEP risk stratification: Combine molecular-autopsy channelopathy panels with wearable cardio-respiratory monitoring to build predictive SUDEP-risk models (F004).
7. Comorbidity integration: Embed structured psychiatric/cognitive screening (shown to detect 1-in-5 cases, 37% previously undiagnosed) into standard epilepsy care pathways and measure QoL outcomes (F006).
8. Cross-species translational pipeline: Leverage naturally epileptic dogs for anti-epileptogenic drug trials before human translation (F010).

Report compiled from 15 confirmed findings and 62 reviewed papers. All quantitative claims are traceable to the cited PMIDs and validated abstract quotes.